Ethereum (ETH) Drops Today, But Could Reach $5.500 With Adam & Eve Pattern
Ethereum (ETH) is traded this Monday (14) at US$ 4.617,18, registering a drop of 2% in the last 24 hours, but still accumulates a up 7% in the week, reinforcing optimism among analysts and investors.
Despite the daily correction, the weekly trajectory demonstrates buying strength, supported by increased liquidity in the altcoin market and the expectation of new macroeconomic catalysts. According to the analysis of Titan of Crypto (@Washigorira), ETH is very close to completing the formation of a chart pattern known as Adam & Eve, a reversal structure that, if confirmed, could propel the price towards a new all-time high.
The expert highlighted:
Ethereum's Adam & Eve pattern #ETH is close to completing its formation. A breakout could take it to $5.500.🟢
This break, according to the technical reading, would open space for Ethereum to seek the region of US$ 5.500, a level that would represent not only a new ATH (All-Time High), but also the consolidation of a medium-term bullish trend.
In this article, we will discuss:
- Market context
- Ethereum (ETH) Next Levels
Market context
The positive sentiment around ETH is also supported by factors such as:
- rollups and layers 2, which continue to attract developers and liquidity;
- the growing integration of Ethereum in Decentralized Finance (DeFi) and tokenization of real-world assets (RWA)
- the strengthening of the market cycle, in line with the recovery of Bitcoin (BTC), which remains stable above US$ 116 thousand.
Ethereum (ETH) Next Levels
If the technical pattern is confirmed, Ethereum could quickly approach the range between $ 5.200 and $ 5.500. However, if there is rejection in the current region, the main supports to watch are close to US$ 4.400 e US$ 4.200, points that have historically attracted strong buyer interest.
This scenario reinforces the perception that Ethereum is in a decisive zone, balancing a short pullback with optimistic prospects for further appreciation in the short and medium term.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint
As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.
"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight
KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.
AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week
Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Crypto prices
More
